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Background
Idiopathic pulmonary fibrosis (IPF) is a progressive
fibro-proliferative disorder of unknown etiology, with no
effective treatment regimen, and a median survival of
just 3–5 years following diagnosis [1]. Pulmonary
Hypertension (PH) often complicates IPF and is asso-
ciated with higher mortality. Augmentation of endogen-
ous natriuretic peptide (NP) stimulated cGMP, using a
neutral endopeptidase inhibitor (NEPi) in combination
with a phosphodiesterase 5 inhibitor (PDE5i), synergisti-
c a l l yp r e v e n t sp a t h o g e n e s i si nah y p o x i cm o d e lo fP H
[2]. Herein, we assessed the efficacy of this novel NEPi/
PDE5i combination therapy in a model of pulmonary
fibrosis.
Methods
Littermate wild-type (WT) and NP receptor-A knockout
(NPR-A KO) mice (male; 20-25g; C57BLK6 background)
were instilled with saline (control) or Bleomycin (Bleo;
1mg/kg) in the absence or presence of the PDE5i sildenafil
(30mg/kg/day; p.o.) or the NEPi ecadotril (60mg/kg/day;
p.o.). Haemodynamic and morphological parameters were
measured 14 days post Bleo administration.
Results
Bleo treatment caused a significant rise in right ventri-
cular systolic pressure (RSVP) in WT mice that was
not reduced by either sildenafil or ecadotril alone, but
significantly inhibited by the combination (Figure 1).
Bleo administration also resulted in right ventricular
hypertrophy (RVH); this was prevented by treatment
with sildenafil, ecadotril or the combination (RV/LV+S;
Control: 0.2486±0.005, Bleo: 0.3054±0.0177, Bleo+sil-
denafil: 0.258±0.006*, Bleo+ecadotril: 0.261±0.008*,
Bleo+combination: 0.247±0.008*; *P<0.05 versus Bleo).
Bleo instillation enhanced total lung collagen accu-
mulation (index of fibrosis) which was ameliorated by
concomitant administration of sildenafil, ecadotril or
the combination (Control: 1.692±0.2, Bleo: 4.4±0.35,
Bleo+combination: 2.124±0.12*; *P<0.05 versus Bleo).
NPR-A KO mice, lacking the bioactivity of ANP and
BNP, exhibited an exaggerated haemodynamic
response to Bleo (WT Bleo RSVP: 31.77±1.96mmHg,
KO Bleo RSVP: 41.68±2.78mmHg; P<0.05), and the
beneficial effects of the combination therapy were lost
(KO Bleo+combination RSVP: 39.84±2.41mmHg;
P>0.05 versus KO Bleo). A similar loss in efficacy of
the combination treatment was observed against RVH
(KO Bleo RV/LV+S: 0.252±0.008, KO Bleo+combina-
tion RV/LV+S: 0.234±0.017; P>0.05). Figure 1.
Conclusion
The NEPi/PDE5i combination is effective in ameliorat-
ing both the haemodynamic aberrations and fibrotic
lung disease in this model. This beneficial pharmacody-
namic activity depends on the bioactivity of NPs, which
represent an endogenous protective mechanism limiting
disease progression. This work substantiates the thera-
peutic potential of manipulating NP and cyclic GMP
signalling for PH and IPF.
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Figure 1 Right ventricular systolic pressure (RVSP) in saline-treated
mice (n=14), and Bleo-treated (n=8) animals in the absence and
presence of sildenafil (SILD, n=7), ecadotril (ECAD; n=8) and
combination treatment (n=9). *P<0.05 versus Bleo alone.
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